Study of Vudalimab or Pembrolizumab in Combination With Chemotherapy as First-line Treatment in Patients With Advanced NSCLC
Xencor, Inc.
Xencor, Inc.
Pfizer
Imugene Limited
Hoffmann-La Roche
Genenta Science
Prelude Therapeutics
Flamingo Therapeutics NV
Teva Branded Pharmaceutical Products R&D, Inc.
Takeda
Ascendis Pharma A/S
Seagen Inc.
Taiho Oncology, Inc.
PharmAbcine
Genmab
HUYABIO International, LLC.
Sanofi
Genome & Company
Merck Sharp & Dohme LLC
Bio-Thera Solutions
Transgene
Gilead Sciences
Sotio Biotech Inc.
Incyte Corporation
Astellas Pharma Inc
Sanofi
BerGenBio ASA
TriSalus Life Sciences, Inc.
Incyte Corporation
ImmuneSensor Therapeutics Inc.
Zai Lab (Hong Kong), Ltd.
Amgen
Sanofi
Sanofi
Iovance Biotherapeutics, Inc.
Mural Oncology, Inc
GlaxoSmithKline
Sanofi
Lava Therapeutics
Ascendis Pharma A/S
Grid Therapeutics
Formycon AG
Mural Oncology, Inc
Triumvira Immunologics, Inc.
Sanofi
Sanofi
Regeneron Pharmaceuticals
Imugene Limited
Turnstone Biologics, Corp.
NovoCure Ltd.
Amgen